CA3248134A1 - CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE - Google Patents

CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE

Info

Publication number
CA3248134A1
CA3248134A1 CA3248134A CA3248134A CA3248134A1 CA 3248134 A1 CA3248134 A1 CA 3248134A1 CA 3248134 A CA3248134 A CA 3248134A CA 3248134 A CA3248134 A CA 3248134A CA 3248134 A1 CA3248134 A1 CA 3248134A1
Authority
CA
Canada
Prior art keywords
seq
designed
cell
cytokine
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248134A
Other languages
English (en)
French (fr)
Inventor
Scott BOYKEN
Marc Lajoie
Thaddeus M. DAVENPORT
Howell MOFFETT
Brian Weitzner
Andrew Howen NG
Paul Joseph SAMPLE
Original Assignee
Outpace Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Outpace Bio Inc filed Critical Outpace Bio Inc
Publication of CA3248134A1 publication Critical patent/CA3248134A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3248134A 2022-01-11 2023-01-11 CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE Pending CA3248134A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263298623P 2022-01-11 2022-01-11
US63/298,623 2022-01-11
US202363479176P 2023-01-09 2023-01-09
US202363479178P 2023-01-09 2023-01-09
US202363479177P 2023-01-09 2023-01-09
US63/479,177 2023-01-09
US63/479,178 2023-01-09
US63/479,176 2023-01-09
PCT/US2023/060508 WO2023137346A2 (en) 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use

Publications (1)

Publication Number Publication Date
CA3248134A1 true CA3248134A1 (en) 2023-07-20

Family

ID=87279672

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248134A Pending CA3248134A1 (en) 2022-01-11 2023-01-11 CYTOKINE COMPOSITIONS DESIGNED AND METHODS OF USE

Country Status (10)

Country Link
US (1) US20250223330A1 (cg-RX-API-DMAC10.html)
EP (1) EP4463469A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025502205A (cg-RX-API-DMAC10.html)
KR (1) KR20240164594A (cg-RX-API-DMAC10.html)
CN (1) CN119053616A (cg-RX-API-DMAC10.html)
AU (1) AU2023208031A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248134A1 (cg-RX-API-DMAC10.html)
IL (1) IL314226A (cg-RX-API-DMAC10.html)
MX (1) MX2024008642A (cg-RX-API-DMAC10.html)
WO (1) WO2023137346A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325764A (en) * 2023-07-13 2026-03-01 Outpace Bio Inc Designed interleukin-2 cytokine compositions and methods for use
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020025287A2 (pt) * 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2023131270A1 (en) * 2022-01-07 2023-07-13 Cure Genetics, Co., Limited Novel interleukin-2 polypeptides

Also Published As

Publication number Publication date
MX2024008642A (es) 2024-09-23
EP4463469A4 (en) 2026-01-14
KR20240164594A (ko) 2024-11-19
JP2025502205A (ja) 2025-01-24
IL314226A (en) 2024-09-01
WO2023137346A3 (en) 2023-11-16
CN119053616A (zh) 2024-11-29
WO2023137346A2 (en) 2023-07-20
US20250223330A1 (en) 2025-07-10
EP4463469A2 (en) 2024-11-20
AU2023208031A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
JP7739547B2 (ja) ヒトドメインを有する抗b細胞成熟抗原キメラ抗原受容体
JP7551815B2 (ja) T細胞療法を向上させるための、哺乳動物t細胞の活性化により誘導可能な合成プロモーター(syn+pro)の作製
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
KR20230079259A (ko) Kras 돌연변이 특이적 t세포 수용체의 스크리닝 및 항종양 용도
KR20210105947A (ko) 나노트랜스포존 조성물 및 사용 방법
US20250223330A1 (en) Designed cytokine compositions and methods of use
CN109336980A (zh) 一种靶向Muc1的嵌合抗原受体修饰T细胞及其用途
US20210347842A1 (en) Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
KR20220105161A (ko) 항원 제시를 위해 세포를 2형 수지상 세포 성분으로 재프로그래밍하기 위한 조성물, 그 방법 및 용도
EP4132543A2 (en) Human immune cells genomically modified to express orthogonal receptors
EP4061835A1 (en) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
CN116635427A (zh) 嵌合抗原受体
CA3180251A1 (en) Cytokine conjugates
KR20260040610A (ko) 설계된 인터루킨-2 사이토카인 조성물 및 사용 방법
WO2025231228A1 (en) Surrogate interferon agonists
KR20260070479A (ko) 항-메소텔린 키메라 항원 수용체 및 사용 방법
CA3133147A1 (en) Core master regulators of glioblastoma stem cells
TW202434618A (zh) 經設計之細胞激素組合物及使用方法
WO2023086517A1 (en) Chimeric antigen receptors
EP3749349A1 (en) Mutant idh1 specific t cell receptor
KR20240095172A (ko) 항원 특이적 t 세포 수용체 및 키메라 공동자극 수용체의 조합
CN120882422A (zh) 一种用于治疗血液癌症的试剂盒
WO2024148185A2 (en) T cell receptors targeting the highly prevalent kras g12v mutation on hla-a*11:01 in lung cancer

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240710

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241203

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250103

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250103

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250220

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251203